2012 ASCO GU Symposium Saturday

San Francisco, CA - 2011 Genitourinary Cancers Symposium - Robert A. Figlin, MD discusses Abstract #348 <br />
Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC) during General Session VIII: Translational Science Session: Renal Cancer at the 2011 Genitourinary Cancers Symposium (GI) meeting at the Marriott Marquis here today, Saturday February 4, 2012. A record 2500 attendees from around the world were on hand to learn the latest treatment and research in Genitourinary cancers from fellow physicians, researchers, health care professionals, cancer survivors and patient advocates. Photo by © ASCO/Todd Buchanan 2012 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.

13 / 13

San Francisco, CA - 2011 Genitourinary Cancers Symposium - Robert A. Figlin, MD discusses Abstract #348
Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC) during General Session VIII: Translational Science Session: Renal Cancer at the 2011 Genitourinary Cancers Symposium (GI) meeting at the Marriott Marquis here today, Saturday February 4, 2012. A record 2500 attendees from around the world were on hand to learn the latest treatment and research in Genitourinary cancers from fellow physicians, researchers, health care professionals, cancer survivors and patient advocates. Photo by © ASCO/Todd Buchanan 2012 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.